Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Centre Leon Berard

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

1 Jun 2022 → ongoing

Decision date (initial)

2024-10-02

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Centre Léon Bérard (CLB) · MSD · Pfizer

External identifiers

EU CT number

2024-513986-38-00

EudraCT number

2021-001065-21

ClinicalTrials.gov

NCT05096390

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Therapy, Safety

To evaluate the efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.

Secondary objectives 5

1. The duration of response (DOR),
2. The best overall response (BOR) using RECIST 1.1,
3. The progression-free survival (PFS),
4. The overall survival (OS),
5. The safety according to NCI CTC-AE v5.

Conditions and MedDRA coding

Locally advanced or metastatic papillary cell carcinoma (PRCC)

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. I1. Age ≥ 18 years on the day of signing informed consent.
2. I2. Metastatic or locally advanced (inoperable) type 2 or mixed PRCC (with or without translocation), histologically confirmed by central review: FFPE blocks (or all HES and IHC slides) with the initial histology report must be sent for central reading before confirmation of inclusion in the study.
3. I3. No prior systemic treatment for renal cancer (chemotherapy, immunotherapy, antiangiogenic drugs, or treatment under evaluation) even in adjuvant setting.
4. I4. At least one measurable site of disease according to RECIST v1.1.
5. I5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1 evaluated within 7 days prior to the date of inclusion.
6. I6. In case of prior radiation therapy, discontinuation of irradiation for at least 3 weeks before first dose of study treatment, with at least 1 site kept/preserved for evaluation. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks - limited field (<10% of the whole body)) to non-CNS disease.
7. I7. Adequate bone-marrow, hepatic, and renal functions within 7 to 9 days prior to randomization, with: - Hemoglobin ≥ 9.0 g/dl ou 5.6 mmol/l, neutrophils ≥ 1 500/mm3 (1.5 G/l), Platelets ≥ 100 000/mm3 (100 G/l), - Serum creatinine ≤ 2 x ULN OR creatinine clearance ≥ 50 ml/min/1.73m2 (calculated using either MDRD or CKD-EPI formula), - AST and ALT ≤ 2.5 x ULN (or ≤ 5 x ULN in case of liver metastasis), - Total serum bilirubin ≤ 1.5 x ULN (or direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 × ULN),
8. I8. Absence of significant proteinuria (<2+) confirmed by urinary dipstick test. If the dipstick test is ≥ 2+, proteinuria will be quantitated on a spot urine sample (protein creatinine ratio
9. I9. Covered by a medical/health insurance.
10. I10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
11. I11.Patients of childbearing potential accepting to use effective contraception or abstain from heterosexual activity during study treatment through 4 months after the last dose of pembrolizumab treatment (or 7 days after the last dose of axitinib as monotherapy) or be surgically sterile.
12. I12. Signed and dated approved informed consent form before any study specific procedures or assessments.

Exclusion criteria 22

1. NI1. Presence of brain metastases on Magnetic Resonance Imaging (MRI) or Computed Tomography-scan (CT-scan) performed within 28 days prior to randomization. Patients with a history of brain metastases treated by surgery or stereotactic surgery, with normal brain MRI or CT-scan are allowed to participate.
2. NI2. Metastases with high risk of nervous compression or bone lesion with high risk of fracture.
3. NI3. Prior history of other malignancies other than PRCC (except for curatively treated basal cell or squamous cell carcinoma of the skin or in situ uterine cervix carcinoma) unless the subjects has been free of the disease for at least 5 years.
4. NI4. Major surgical procedure, open biopsy, or serious none healing wound within 28 days prior to inclusion.
5. NI5. Significant cardiovascular disease, including: -Disorder of left ventricular function with a left ventricular ejection fraction (LVEF) < 50%, -Uncontrolled arterial hypertension under adapted medication: systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg or both despite appropriate therapy, blood pressure must be monitored and controlled before inclusion, or patients under 3 antihypertensive therapies at screening, -Myocardial infarction, severe angina, or unstable angina within 6 months prior to inclusion, -History of serious ventricular arrhythmia (ie ventricular tachycardia or ventricular fibrillation), -Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication), -Coronary or peripheral artery bypass graft or active coronary stent within 6 months prior to inclusion, -Veinous thrombosis or pulmonary embolism within 6 months prior to inclusion.
6. NI6. Anti-coagulation therapy with vitamin K antagonist. Anti-coagulation therapy must have been administered for more than a month prior study treatment beginning.
7. NI7. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
8. NI8. History of any allograft.
9. NI9. Known history of HIV or HBV infection, or known active HCV infection.
10. NI10. Any active acute or chronic or uncontrolled infection/disorder that would impair the ability to evaluate the patient or the ability for the patient to complete the study.
11. NI11. Known history of active TB (Bacillus Tuberculosis).
12. NI12. Interstitial lung disease, respiratory insuffisancy whatever the cause.
13. NI13. Prior (non-infectious) pneumonitis requiring systemic corticosteroid therapy or current pneumonitis.
14. NI14. Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea.
15. NI15. History of severe hypersensitivity to another monoclonal antibody.
16. NI16. Known hypersensitivity to the active substances or to any of the excipients.
17. NI17. Receiving or having received immunosuppressive therapy or corticosteroids within 1 month prior to inclusion (except for hydrocortisone for substitution purposes).
18. NI18. Live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed if non-living/inactivated.
19. NI19. Psychological, familial, sociological, or geographical conditions that would limit compliance with study protocol requirements or known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
20. NI20. Inclusion in another clinical trial, except for supportive care trials.
21. NI21. Pregnant or breastfeeding woman or patient expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 4 months after the last dose of study treatment (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential).
22. NI22. Under or requiring tutorship or curatorship.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Objective response rate (ORR)

Secondary endpoints 5

1. The duration of response (DOR)
2. The best overall response (BOR),
3. The progression-free survival (PFS),
4. The overall survival (OS),
5. The safety according to NCI CTC-AE v5.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Leon Berard

Sponsor organisation

Centre Leon Berard

Address

28 Rue Laennec

City

Lyon

Postcode

69008

Country

France

Scientific contact point

Organisation

Centre Leon Berard

Contact name

Coordinating investigators

Public contact point

Organisation

Centre Leon Berard

Contact name

Coordinating investigators

Locations

1 EU/EEA country · 14 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 10 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications